KR102865323B1 - 트리아졸 글리콜레이트 옥시다아제 억제제 - Google Patents
트리아졸 글리콜레이트 옥시다아제 억제제Info
- Publication number
- KR102865323B1 KR102865323B1 KR1020217003486A KR20217003486A KR102865323B1 KR 102865323 B1 KR102865323 B1 KR 102865323B1 KR 1020217003486 A KR1020217003486 A KR 1020217003486A KR 20217003486 A KR20217003486 A KR 20217003486A KR 102865323 B1 KR102865323 B1 KR 102865323B1
- Authority
- KR
- South Korea
- Prior art keywords
- triazole
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US62/694,918 | 2018-07-06 | ||
| US201962827573P | 2019-04-01 | 2019-04-01 | |
| US62/827,573 | 2019-04-01 | ||
| PCT/US2019/040690 WO2020010309A1 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210041564A KR20210041564A (ko) | 2021-04-15 |
| KR102865323B1 true KR102865323B1 (ko) | 2025-09-26 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217003486A Active KR102865323B1 (ko) | 2018-07-06 | 2019-07-05 | 트리아졸 글리콜레이트 옥시다아제 억제제 |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279952B2 (en) | 2018-07-06 | 2024-11-01 | Cantero Therapeutics Inc | Triazole glycolate oxidase inhibitors |
| WO2021086874A1 (en) | 2019-11-01 | 2021-05-06 | GyanRx Sciences, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| WO2021142155A1 (en) * | 2020-01-08 | 2021-07-15 | Orfan Biotech Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| TW202339727A (zh) * | 2021-10-11 | 2023-10-16 | 美商坎特羅治療股份有限公司 | 使用1h-1,2,3-三唑-4-羧酸之治療方法 |
| WO2024109917A1 (zh) * | 2022-11-25 | 2024-05-30 | 西藏海思科制药有限公司 | 一种三唑衍生物及其在医药上的应用 |
| WO2024212137A1 (en) * | 2023-04-12 | 2024-10-17 | Cantero Therapeutics, Inc. | Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100266A1 (en) * | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (ja) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | ベンゾピラノトリアゾ−ル誘導体 |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| CN101307307A (zh) * | 2008-07-11 | 2008-11-19 | 华东理工大学 | 一种乙醇酸氧化酶制剂、制备方法及应用 |
| KR20140108594A (ko) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| JP5455279B1 (ja) | 2012-10-25 | 2014-03-26 | アサヒグループホールディングス株式会社 | ラテックスの増産方法 |
| TW201437200A (zh) | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (fr) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | Methode et composition pour ameliorer la productivite de plantes non legumineuses |
| JP5866035B1 (ja) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | 有効分げつ促進方法 |
| US10766829B2 (en) | 2015-03-19 | 2020-09-08 | KOHJIN Life Sciences Co., Ltd. | Yeast extract having effect of promoting growth of plant and elongation of root and effect of improving added values of plant |
| BR112020013073A2 (pt) * | 2017-12-29 | 2020-12-01 | Biomarin Pharmaceutical Inc. | composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo |
| WO2019133813A1 (en) | 2017-12-29 | 2019-07-04 | Orfan Biotech Inc. | Glycolate oxidase inhibitors and use thereof |
| WO2019165159A1 (en) | 2018-02-23 | 2019-08-29 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| IL279952B2 (en) | 2018-07-06 | 2024-11-01 | Cantero Therapeutics Inc | Triazole glycolate oxidase inhibitors |
| EP3986863A4 (en) | 2019-06-19 | 2023-01-18 | BioMarin Pharmaceutical Inc. | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES |
-
2019
- 2019-07-05 IL IL279952A patent/IL279952B2/en unknown
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/pt unknown
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 KR KR1020217003486A patent/KR102865323B1/ko active Active
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
- 2019-07-05 AU AU2019297523A patent/AU2019297523B2/en active Active
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en not_active Ceased
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/es unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873B/zh active Active
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/ja active Active
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/es unknown
-
2021
- 2021-01-03 SA SA521420951A patent/SA521420951B1/ar unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/es unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100266A1 (en) * | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
Also Published As
| Publication number | Publication date |
|---|---|
| SA521420951B1 (ar) | 2024-03-24 |
| JP7348705B2 (ja) | 2023-09-21 |
| US20210403439A1 (en) | 2021-12-30 |
| JP2021530560A (ja) | 2021-11-11 |
| MX2021000051A (es) | 2021-03-25 |
| SG11202012930RA (en) | 2021-01-28 |
| AU2019297523B2 (en) | 2025-04-17 |
| WO2020010309A1 (en) | 2020-01-09 |
| CN112399873B (zh) | 2024-10-25 |
| CA3104529A1 (en) | 2020-01-09 |
| IL279952B2 (en) | 2024-11-01 |
| KR20210041564A (ko) | 2021-04-15 |
| IL279952B1 (en) | 2024-07-01 |
| US11401246B2 (en) | 2022-08-02 |
| AU2019297523A1 (en) | 2021-02-25 |
| US20230143491A1 (en) | 2023-05-11 |
| EP3817816A1 (en) | 2021-05-12 |
| WO2020010309A9 (en) | 2020-01-30 |
| CN112399873A (zh) | 2021-02-23 |
| PE20210859A1 (es) | 2021-05-18 |
| IL279952A (en) | 2021-03-01 |
| CO2021001277A2 (es) | 2021-04-30 |
| BR112021000050A2 (pt) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7348705B2 (ja) | トリアゾールグリコール酸オキシダーゼ阻害剤 | |
| ES3043183T3 (en) | Compounds and uses thereof | |
| WO2023062575A1 (en) | Cyclic vinyl sulfone compounds as wrn inhibitors | |
| KR101593288B1 (ko) | 항균제로서 유용한 플루오로-피리디논 유도체 | |
| KR101739361B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| JP2021512092A (ja) | Prc2阻害剤 | |
| WO2011139891A1 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites | |
| EA024702B1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| CN110655503A (zh) | 取代的三唑类化合物、包含其的药物组合物、其制备方法及其用途 | |
| KR102826937B1 (ko) | Axl 및 c-Met 키나아제 억제 활성을 갖는 화합물 및 이의 제조와 응용 | |
| ES3049309T3 (en) | Processes for preparing triazole glycolate oxidase inhibitors | |
| US7482369B2 (en) | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | |
| US20210171503A1 (en) | Glycolate oxidase inhibitors and use thereof | |
| KR20230016646A (ko) | 치환된 피라졸릴 화합물 및 이의 사용 방법 | |
| CN109641909B (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
| WO2015024016A2 (en) | 2-piperidinyl substituted n,3-dihydroxybutanamides | |
| US20230295110A1 (en) | Phd inhibitor compounds, compositions, and methods of use | |
| CA3104529C (en) | Triazole glycolate oxidase inhibitors | |
| EP1572686B1 (en) | Anthranilic acid amide derivatives and their pharmaceutical use | |
| CN118994047B (zh) | 一种水杨醛衍生物及其用途 | |
| WO2024212137A1 (en) | Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound | |
| WO2025096495A1 (en) | Aryl fluorosulfate-based inhibitors as novel antitubercular agents | |
| HK1191951B (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| HK40002867A (en) | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |